<DOC>
	<DOCNO>NCT01852175</DOCNO>
	<brief_summary>Recently , two P2Y12 receptor inhibitor approve clinical use : prasugrel ticagrelor . Both prasugrel ticagrelor show associated potent antiplatelet effect compare clopidogrel associate improved net clinical benefit . However , date limit head-to-head comparison two new agent .</brief_summary>
	<brief_title>Pharmacodynamic Effects Prasugrel Compared With Ticagrelor Patients With Coronary Artery Disease</brief_title>
	<detailed_description>Dual antiplatelet therapy consist aspirin clopidogrel cornerstone treatment prevention thrombotic event patient coronary artery disease ( CAD ) undergo percutaneous coronary intervention ( PCI ) . However , considerable number patient continue recurrent ischemic event despite treatment regimen . These observation underscore need potent antiplatelet therapy . Recently , two P2Y12 receptor inhibitor approve clinical use : prasugrel ticagrelor . Both prasugrel ticagrelor show associated potent antiplatelet effect compare clopidogrel . These favorable pharmacodynamic effect translate reduce ischemic event rate , expense increase risk bleeding patient acute coronary syndrome . Overall , drug associate improved net clinical benefit . These finding large-scale clinical investigation lead approval prasugrel ticagrelor . However , date limit head-to-head comparison two new agent .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients know coronary artery disease On maintenance treatment aspirin ( 81 mg per day ) clopidogrel ( 75 mg per day ) least 1month per standard care . Age 18 74 year old . History stroke , transient ischemic attack intracranial bleeding . Known allergy aspirin , prasugrel , ticagrelor , clopidogrel . Weight &lt; 60kg On treatment oral anticoagulation ( coumarin derivate , dabigatran ) . Hemoglobin &lt; 10 gm/dL Platelet count &lt; 80x106/mL Active bleed hemodynamic instability . Creatinine Clearance &lt; 30 mL/minute . Baseline ALT &gt; 2.5 time upper limit normal . Patients sick sinus syndrome ( SSS ) high degree AV block without pacemaker protection . Drugs interfere 2C19 metabolism ( avoid interaction clopidogrel ) : , fluconazole ( Diflucan ) , ketoconazole ( Nizoral ) , voriconazole ( VFEND ) , etravirine ( Intelence ) , felbamate ( Felbatol ) , fluoxetine ( Prozac , Serafem , Symbyax ) , fluvoxamine ( Luvox ) , ticlopidine ( Ticlid ) . Drugs interfere CYP3A4 metabolism ( avoid interaction Ticagrelor ) : Ketoconazole , itraconazole , voriconazole , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , telithromizycin . Pregnant females* . *Women childbearing age must use reliable birth control ( i.e . oral contraceptive ) participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Dual antiplatelet therapy</keyword>
	<keyword>prasugrel</keyword>
	<keyword>ticagrelor</keyword>
</DOC>